The product, manufactured by Ranbaxy, would be sold in the US under the Teva label and marketed by Teva USA, a company release said.
As per the agreement, Israel-headquartered Teva would distribute the product and the two companies would have share in the profit.
The launch follows Teva's relinquishment of its right to a 180-day period of marketing exclusivity for Quinapril HCL tablets (5mg, 10 mg, 20 mg and 50 mg), it added.
Quinapril, which has an annual sale of about $55 million, is the AB-rated generic equivalent of Parke Davis' anti-hypertensive agent Accupril tablets.
